CAR-T therapy followed by haploidentical HSCT have prominent therapeutic efficacy for patients with relapsed/refractory acute lymphoblastic leukemia

Conditions

refractory/relapsed acute lymphoblastic leukemia

Zhao H, Lin Z, Zheng H, Wei G, Luo Y, Shi J, Cui Q, Zhao M, Liang A, Zhang Q, Yang J, Li X, Chen J, Song X, Jing H, Li Y, Hao S, Wu W, Yin ETS, Tan Y, Yu J, Zhao Y, Lai X, Wei Y, Li P, Huang J, Wang T, Blaise D, Xiao L, Chang AH, Nagler A, Leung G, Mohty M, Huang H, Hu Y.

2026-05-13

10.1002/ajh.70361

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.

Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, Zhao M, Liang A, Zhang Q, Yang J, Li X, Chen J, Song X, Jing H, Li Y, Hao S, Wu W, Tan Y, Yu J, Zhao Y, Lai X, Yin ETS, Wei Y, Li P, Huang J, Wang T, Blaise D, Xiao L, Chang AH, Nagler A, Mohty M, Huang H, Hu Y.

2020-05-0464 citations

10.1186/s13045-020-00873-7

Interventions

Group A:CAR-T followed by haploHSCT

Group B:CAR-T therpay without haploidentical HSCT

Eligibility

Sex/Gender

All

Age

No minimum to 70 Years

Inclusion criteria

Inclusion criteria: 1. refractory/relapsed acute lymphoblastic leukemia; 2. received CAR-T followed by haplo-HSCT; 3. younger than 70 years old.

Exclusion criteria

Exclusion criteria: 1. complicated with organs dysfunction; 2. complicated with severe infection; 3. complicated with infectious disease.

Design outcomes

Primary

Measure	Time frame
Overall survival;leukemia free survival;	—

Secondary

Measure	Time frame
acute graft versus host disease;infection rate;	—

Countries

China

Contacts

Public ContactHe Huang

Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed